TuHURA Biosciences, Inc. cash flow to debt ratio of -3.95K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

TuHURA Biosciences, Inc.'s free cash flow has decreased 87.37% from $-14.79M last year to $-27.71M, signaling decreasing performance

TuHURA Biosciences, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

TuHURA Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.02 today, signaling weakened financials

TuHURA Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

TuHURA Biosciences, Inc.'s interest coverage ratio is -49.46, which means that the company struggles to meet interest obligations, signaling financial risk.

TuHURA Biosciences, Inc. has insufficient data to evaluate this check.

TuHURA Biosciences, Inc.'s short-term liabilities of $5.92M exceed its short-term assets of $4.62M, signaling financial risk

TuHURA Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TuHURA Biosciences, Inc.'s return on equity of -153.99%, is lower than 15.00%, indicating bad performance

TuHURA Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TuHURA Biosciences, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

TuHURA Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TuHURA Biosciences, Inc. has negative free cash flow, indicating cash burn

TuHURA Biosciences, Inc.'s yearly earnings has decreased 38.64% since last year from $-21.68M to $-30.06M, signaling decreasing performance

TuHURA Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -135.50% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TuHURA Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

TuHURA Biosciences, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

TuHURA Biosciences, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

TuHURA Biosciences, Inc. has insufficient data to evaluate this check.

TuHURA Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TuHURA Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

TuHURA Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TuHURA Biosciences, Inc. has insufficient data to evaluate this check.

TuHURA Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TuHURA Biosciences, Inc. has a price-to-book ratio of 5.59x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

TuHURA Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue